
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is positioned to see future success through its strong portfolio pipeline and experienced leadership with significant stock ownership. However, the company's success is dependent on the timely development and commercialization of new products, which carries a high level of risk. The significant ownership of two company directors may also pose a potential conflict of interest in corporate matters.
Bears say
Amphastar Pharma is facing challenges with their base pharmaceutical business, reflecting a decline in sales of their injectable glucagon product and generic epinephrine. Despite the recent approval of AMP-007 and the potential launch of other products, pricing pressures and competition limit their potential for significant growth. The company is also struggling with the pricing headwinds of their flagship product Baqsimi and a lack of near-term catalysts to drive growth. These factors, along with continued competition and higher R&D costs, contribute to our negative outlook on Amphastar Pharma's stock.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares